Fig. 4From: CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in gliomalncGRS-1 is required for the proliferation of primary, patient-derived glioma cells. a RT-qPCR of lncGRS-1 transcript levels following CRISPRi-mediated knockdown in GBM SF10360 and DIPG SF8628 (n = 2 biological replicates per condition; error bars = SD). b Internally controlled, growth assays of GBM SF10360 and DIPG SF8628 cells with CRISPRi-mediated knockdown of lncGRS-1 (n = 2 biological replicates per condition; error bars = SD). c RT-qPCR of lncGRS-1 transcript levels following ASO-mediated knockdown of GBM SF10360 and DIPG SF8628 (n = 2 biological replicates per condition; error bars = SD). d Cell propagation time course of GBM SF10360 and DIPG SF8628 cells with ASO-mediated knockdown of lncGRS-1. ASOs were re-transfected at day 7 (n = 2 biological replicates per condition; error bars = SD)Back to article page